| Literature DB >> 35854273 |
Joy Zhao1, Julie A Barta2, Russell McIntire3, Christine Shusted2, Charnita Zeigler-Johnson4, Hee-Soon Juon5.
Abstract
BACKGROUND: The inverse relationship between BMI and lung cancer diagnosis is well defined. However, few studies have examined the racial differences in these relationships. The purpose of this paper is to explore the relationships amongst race, BMI, and lung cancer diagnosis using the National Lung Screening Trial (NLST) data.Entities:
Keywords: BMI; Lung cancer diagnosis; NLST; Race
Mesh:
Year: 2022 PMID: 35854273 PMCID: PMC9297592 DOI: 10.1186/s12885-022-09888-4
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.638
Background and clinical characteristics and lung cancer diagnosis in the National Lung Screening Trial (NLST) (n = 53,452)
| 31,530 | 59.0% | |
| 61.42 ± 5.02 | ||
| Non-Hispanic Whites | 47,744 | 90.0% |
| Non-Hispanic African Americans | 2,341 | 4.4% |
| Other Races | 2,942 | 5.6% |
| < High school | 3,249 | 6.2% |
| High school graduate + | 32,423 | 62.1% |
| College graduates | 16,546 | 31.7% |
| Former | 27,692 | 51.8% |
| Current | 25,760 | 48.2% |
| 55.9 ± 23.9 | ||
| 11,037 | 20.7% | |
| 2,690 | 5.1% | |
| Underweight/Normal (< 25) | 15,320 | 28.9% |
| Overweight (25–29.99) | 22,761 | 42.9% |
| Obese (> = 30) | 15,009 | 28.2% |
| 2,058 | 3.9% | |
| Stage I | 831 | 40.4% |
| Stage II | 146 | 7.1% |
| Stage III | 459 | 22.3% |
| Stage IV | 596 | 28.9% |
| No stage recorded | 26 | 1.3% |
| Adenocarcinoma | 902 | 44.4% |
| Squamous cell carcinoma | 462 | 22.7% |
| Large cell carcinoma | 52 | 2.6% |
| Small cell carcinoma | 287 | 14.1% |
| Carcinoid/ Neuroendocrine tumor | 60 | 3.0% |
| Non-small cell carcinoma or other | 271 | 13.3% |
Relationship of race, BMI, and lung cancer development
| .001 | |||||||
| Non-Hispanic Whites (NHW) | 13,725 | 28.8% | 20,484 | 43.1% | 13,385 | 28.1% | |
| African-Americans | 621 | 26.7% | 917 | 39.3% | 787 | 33.9% | |
| Others | 896 | 30.6% | 1,264 | 43.1% | 771 | 26.3% | |
| Total | 747 | 4.9% | 867 | 3.8% | 423 | 2.8% | .001 |
| NHW | 678 | 4.9% | 794 | 3.8% | 387 | 2.8% | .001 |
| African-Americans | 32 | 5.1% | 46 | 4.9% | 24 | 3.0% | .083 |
| Others | 21 | 4.9% | 13 | 2.7% | 2 | 1.2% | .041a |
| .144 | |||||||
| Stage I & II | 343 | 46.4% | 435 | 50.7% | 191 | 46.0% | |
| Stage III & IV | 396 | 53.5% | 423 | 49.3% | 224 | 54.0% | |
| .03 | |||||||
| Adenocarcinoma | 331 | 45.0% | 393 | 45.8% | 166 | 39.7% | |
| Squamous cell carcinoma | 152 | 20.7% | 217 | 25.3% | 89 | 21.3% | |
| Small cell carcinoma | 106 | 14.4% | 107 | 12.5% | 72 | 17.2% | |
| Carcinoid/Neuroendocrine tumor | 18 | 2.5% | 22 | 2.6% | 19 | 4.6% | |
| Large cell carcinoma | 20 | 2.7% | 19 | 2.2% | 13 | 3.1% | |
| Non-Small cell carcinoma or other | 109 | 14.8% | 101 | 11.8% | 59 | 14.1% | |
a Fisher exact test
Multivariate analysis of lung cancer diagnosis by race
| 51,930 | 46,554 | 2,299 | 3,077 | |||||
|---|---|---|---|---|---|---|---|---|
| Whites | 1.00 | |||||||
| African-American | 1.20 | 0.97–1.48 | ||||||
| Others | 0.77 | 0.63–0.96* | ||||||
| Underweight/Normal | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Overweight | 0.83 | 0.75–0.93* | 0.83 | 0.75–0.93* | 1.03 | 0.64–1.66 | 0.72 | 0.45–1.15 |
| Obese | 0.63 | 0.56–0.72* | 0.64 | 0.56–0.73* | 0.72 | 0.41–1.25 | 0.53 | 0.29–0.87* |
Note. Adjusted for age, gender, education, family history of lung cancer, COPD, smoking status, and pack-years
*p<0.05